arrow
S

Shahin Merat

Tehran University of Medical Sciences
H指数:52
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

丙型肝炎病毒患病率的全球变化以及护理2015年和2020的级联: 一项建模研究

2022-05-01368
OAAI
Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER)
2021-11-2815
OA
SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial (vol 70, pg 2206, 2020)
2021-04-150
OAAI
Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial
2020-08-1969
OAAI
Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial
2020-08-1988
OAAI
Household Fuel Use and the Risk of Gastrointestinal Cancers: The Golestan Cohort Study
2020-06-0124
OAAI
The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017

1990至2017 195个国家和地区因肝硬化造成的全球,区域和国家负担: 全球疾病负担研究2017的系统分析

2020-03-01899
OAAI
The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment
2020-02-0514
PREAI
The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017

1990至2017 195个国家和地区炎症性肠病的全球、区域和国家负担: 全球疾病负担研究2017的系统分析

2020-01-011.4K
OAAI